Details
Related items

SEXIE-R-CHOP-14

Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)

LHA ID: 7WF0ERG3ME-9

Projects: GLA - German Lymphoma Alliance

Investigation position:

Help

Tree Split Graph

Export PNG

Click below to download a copy of the image

Download

Creators and Submitter

Creator

Marita Ziepert

Submitter

René Hänsel

Activity

Views: 2140

Created: 16th May 2019 at 15:55

Last updated: 16th May 2019 at 15:55

Related items

Projects (1)
Studies (1)
Resources (2)
Publications (1)
Data files (5)
People (2)
Programmes (1)

GLA - German Lymphoma Alliance

B-cell lymphoma is the most frequent lymphoid neoplasia accounting for one third of all lymphomas. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) is the current treatment standard, leading to high cure rates especially in younger patients. Although the 3-year event-free survival is about 60% even for elderly patients between 60-80 years old, the remainder of patients eventually relapse and the majority die of their disease. The German Non-Hodgkin's Lymphoma Study ...

Programme: NHL

Public web page: https://www.dshnhl.org

Organisms: Homo sapiens

Human Diseases: non-Hodgkin lymphoma, B-cell lymphoma

SEXIE-R-CHOP-14

GLA - German Lymphoma Alliance

All creators

Marita Ziepert

Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)

Submitter: René Hänsel

Investigation: SEXIE-R-CHOP-14

Resources: SEXIE-R-CHOP-14 metadata, SEXIE-R-CHOP-14 trial data

Study type: Not specified

Snapshots: No snapshots

Created: 16th May 2019 at 15:57, Last updated: 25th Mar 2021 at 15:44

SEXIE-R-CHOP-14 trial data

GLA - German Lymphoma Alliance

All creators

Marita Ziepert

Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival) Sample Size: 268

Submitter: René Hänsel

Resource type: Experimental Assay Type

Technology type: Technology Type

Investigation: SEXIE-R-CHOP-14

Study: SEXIE-R-CHOP-14

Human Diseases: diffuse large B-cell lymphoma

Data files: SEXIE-R-CHOP-14 trial data-CSV, SEXIE-R-CHOP-14 trial data-ODM, SEXIE-R-CHOP-14 trial data-SPSS

Snapshots: No snapshots

Created: 16th May 2019 at 15:59, Last updated: 29th Oct 2019 at 10:57

SEXIE-R-CHOP-14 metadata

GLA - German Lymphoma Alliance

All creators

Marita Ziepert

Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival) Sample Size: 268

Submitter: René Hänsel

Resource type: Experimental Assay Type

Technology type: Technology Type

Investigation: SEXIE-R-CHOP-14

Study: SEXIE-R-CHOP-14

Human Diseases: diffuse large B-cell lymphoma

Data files: SEXIE-R-CHOP-14 metadata-ODM, SEXIE-R-CHOP-14 metadata-XLSX

Snapshots: No snapshots

Created: 16th May 2019 at 15:58, Last updated: 29th Oct 2019 at 10:57

Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.

GLA - German Lymphoma Alliance

(Show All)

All authors

Markus Löffler

Samira Zeynalova

Marita Ziepert

Abstract (Expand)

Male sex is associated with unfavourable pharmacokinetics and prognosis in elderly patients with diffuse large B-cell lymphoma (DLBCL). We investigated higher rituximab doses for elderly male DLBCL … patients. Elderly patients (61-80 years) received 6 cycles CHOP-14 (cyclophosphamide, doxorubicin, vincristine and prednisone at 14-day intervals) and were randomized to 8 cycles rituximab (males 500 mg/m(2) , females 375 mg/m(2) ) every 2 weeks or according to an upfront dose-dense schedule. In 268 (120 females, 148 males) no difference between the standard and the upfront dose-dense rituximab schedule was found (3-year PFS 72% vs. 74%; OS 74% vs. 77%; P = 0.651). The 500 mg/m(2) dose of rituximab for male patients was associated with serum levels and exposure times slightly better than in females and a male/female hazard ratio of 0.9 for progression-free survival (PFS) and 0.8 for overall survival. For elderly males, 500 mg/m(2) was not more toxic than 375 mg/m(2) rituximab, but improved PFS by 32.5% (P = 0.039), with a trend for a (30%) better overall survival (P = 0.076) in a planned subgroup analysis adjusting for International Prognostic Index risk factors. We conclude that the higher rituximab dose for elderly male patients abrogated the adverse prognosis of male sex without increasing toxicity. In the era of personalized medicine, sex-specific pharmacokinetics and toxicities should be investigated for all drugs where these parameters impact on outcome.

Authors: M. Pfreundschuh, N. Murawski, S. Zeynalova, M. Ziepert, M. Loeffler, M. Hanel, J. Dierlamm, U. Keller, M. Dreyling, L. Truemper, N. Frickhofen, A. N. Hunerliturkoglu, N. Schmitz, V. Poschel, T. Rixecker, C. Berdel, C. Rube, G. Held, C. Zwick